Whereas, during treatment, enzalutamide induced elevated levels of HMGB1 expression, recruitment and activation of tumor-associated macrophages to secrete interleukin 6 led to enzalutamide resistance (91). The gene discussed is HMGB1; the disease is neoplasm.